Royalty Pharma (RPRX) Stock Forecast, Price Target & Predictions
RPRX Stock Forecast
Royalty Pharma stock forecast is as follows: an average price target of $43.33 (represents a 59.30% upside from RPRX’s last price of $27.20) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
RPRX Price Target
The average price target for Royalty Pharma (RPRX) is $43.33 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $51.00 to $28.00. This represents a potential 59.30% upside from RPRX's last price of $27.20.
RPRX Analyst Ratings
According to 6 Wall Street analysts, Royalty Pharma's rating consensus is 'Buy'. The analyst rating breakdown for RPRX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Royalty Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Chris Shibutani | Goldman Sachs | $51.00 | $29.16 | 74.93% | 87.50% |
| Jul 11, 2024 | Terence Flynn | Morgan Stanley | $51.00 | $25.73 | 98.21% | 87.50% |
| Jun 07, 2024 | Chris Shibutani | Goldman Sachs | $50.00 | $27.09 | 84.57% | 83.82% |
| Jun 03, 2024 | Ashwani Verma | UBS | $28.00 | $27.35 | 2.38% | 2.94% |
| Dec 06, 2022 | - | Morgan Stanley | $51.00 | $42.87 | 18.96% | 87.50% |
| Jun 13, 2022 | Ashwani Verma | UBS | $47.00 | $38.46 | 22.20% | 72.79% |
The latest Royalty Pharma stock forecast, released on Sep 04, 2024 by Chris Shibutani from Goldman Sachs, set a price target of $51.00, which represents a 74.93% increase from the stock price at the time of the forecast ($29.16), and a 87.50% increase from RPRX last price ($27.20).
Royalty Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $51.00 | $45.00 |
| Last Closing Price | $27.20 | $27.20 | $27.20 |
| Upside/Downside | -100.00% | 87.50% | 65.44% |
In the current month, the average price target of Royalty Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Royalty Pharma's last price of $27.20. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Aug 13, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Jul 11, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jun 12, 2024 | Johnson Rice | Overweight | Overweight | Hold |
| Jun 12, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jun 07, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Jun 03, 2024 | UBS | Buy | Neutral | Downgrade |
| May 23, 2024 | Needham | Buy | Buy | Hold |
| May 17, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Dec 06, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
Royalty Pharma's last stock rating was published by Goldman Sachs on Sep 04, 2024. The company gave RPRX a "Buy" rating, the same as its previous rate.
Royalty Pharma Financial Forecast
Royalty Pharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $536.31M | $538.20M | $683.97M | $565.75M | $573.46M | $535.96M | $562.05M | $575.70M | $585.77M | $554.96M | $573.03M | $572.14M | $538.40M | $507.62M |
| Avg Forecast | $853.00M | $804.00M | $700.00M | $772.00M | $697.66M | $696.92M | $627.42M | $665.57M | $685.52M | $631.74M | $543.70M | $902.02M | $1.06B | $586.32M | $528.36M | $597.01M | $552.06M | $563.10M | $484.33M | $511.72M | $483.97M | $451.66M | $468.93M |
| High Forecast | $853.00M | $804.00M | $700.00M | $772.00M | $697.66M | $702.55M | $627.42M | $665.57M | $708.87M | $659.14M | $543.70M | $902.02M | $1.06B | $586.32M | $528.36M | $597.01M | $552.06M | $563.10M | $484.33M | $511.72M | $483.97M | $451.66M | $468.93M |
| Low Forecast | $853.00M | $804.00M | $700.00M | $772.00M | $697.66M | $691.28M | $627.42M | $665.57M | $662.16M | $615.78M | $543.70M | $902.02M | $1.06B | $586.32M | $528.36M | $597.01M | $552.06M | $563.10M | $484.33M | $511.72M | $483.97M | $451.66M | $468.93M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.85% | 0.99% | 0.76% | 0.53% | 0.98% | 1.01% | 0.94% | 1.04% | 1.04% | 1.15% | 1.12% | 1.18% | 1.19% | 1.08% |
Royalty Pharma's average Quarter revenue forecast for Dec 23 based on 2 analysts is $685.52M, with a low forecast of $662.16M, and a high forecast of $708.87M. RPRX's average Quarter revenue forecast represents a 27.82% increase compared to the company's last Quarter revenue of $536.31M (Sep 23).
Royalty Pharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | $167.95M | $248.84M | $527.47M | $169.00M | $192.19M | $388.41M | $233.56M | $60.67M | $152.05M | $483.94M | $112.20M | $208.94M | $322.08M | $482.00M |
| Avg Forecast | $615.43M | $580.08M | $505.04M | $556.99M | $503.36M | $502.82M | $452.68M | $148.95M | $494.59M | $455.79M | $392.27M | $135.41M | $65.90M | $423.03M | $381.21M | $123.10M | $398.31M | $406.27M | $349.44M | $174.00M | $349.18M | $325.86M | $387.18M |
| High Forecast | $615.43M | $580.08M | $505.04M | $556.99M | $503.36M | $506.88M | $452.68M | $178.74M | $511.44M | $475.56M | $392.27M | $162.50M | $79.08M | $423.03M | $381.21M | $147.72M | $398.31M | $406.27M | $349.44M | $208.80M | $349.18M | $325.86M | $464.61M |
| Low Forecast | $615.43M | $580.08M | $505.04M | $556.99M | $503.36M | $498.75M | $452.68M | $119.16M | $477.74M | $444.28M | $392.27M | $108.33M | $52.72M | $423.03M | $381.21M | $98.48M | $398.31M | $406.27M | $349.44M | $139.20M | $349.18M | $325.86M | $309.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.37% | 0.63% | 3.90% | 2.56% | 0.45% | 1.02% | 1.90% | 0.15% | 0.37% | 1.38% | 0.64% | 0.60% | 0.99% | 1.24% |
2 analysts predict RPRX's average Quarter EBITDA for Dec 23 to be $494.59M, with a high of $511.44M and a low of $477.74M. This is 194.49% upper than Royalty Pharma's previous annual EBITDA (Sep 23) of $167.95M.
Royalty Pharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | $72.11M | $227.63M | $340.75M | $-610.17M | $217.83M | $304.50M | $-39.87M | $6.70M | $101.93M | $440.78M | $69.12M | $171.09M | $290.63M | $442.07M |
| Avg Forecast | $811.80M | $656.60M | $662.57M | $602.88M | $638.65M | $553.64M | $576.21M | $73.78M | $602.90M | $459.35M | $495.44M | $67.08M | $8.58M | $423.28M | $466.25M | $60.98M | $462.84M | $418.12M | $419.64M | $107.19M | $420.82M | $352.82M | $355.11M |
| High Forecast | $811.80M | $656.60M | $662.57M | $602.88M | $638.65M | $565.29M | $576.29M | $88.54M | $608.87M | $513.04M | $495.44M | $80.49M | $10.30M | $423.28M | $466.25M | $73.17M | $462.84M | $418.12M | $419.64M | $128.63M | $420.82M | $352.82M | $426.13M |
| Low Forecast | $811.80M | $656.60M | $662.57M | $602.88M | $638.65M | $530.33M | $576.12M | $59.03M | $596.93M | $405.66M | $495.44M | $53.66M | $6.87M | $423.28M | $466.25M | $48.78M | $462.84M | $418.12M | $419.64M | $85.75M | $420.82M | $352.82M | $284.09M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.16% | 0.46% | 5.08% | -71.08% | 0.51% | 0.65% | -0.65% | 0.01% | 0.24% | 1.05% | 0.64% | 0.41% | 0.82% | 1.24% |
Royalty Pharma's average Quarter net income forecast for Dec 23 is $602.90M, with a range of $596.93M to $608.87M. RPRX's average Quarter net income forecast represents a 736.04% increase compared to the company's last Quarter net income of $72.11M (Sep 23).
Royalty Pharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | $57.23M | $47.63M | $85.69M | $73.23M | $50.69M | $51.84M | $51.54M | $46.16M | $48.59M | $44.92M | $43.16M | $250.31M | $22.74M | $92.50M |
| Avg Forecast | $73.41M | $69.19M | $60.24M | $66.44M | $60.04M | $59.98M | $54.00M | $73.47M | $59.00M | $54.37M | $46.79M | $66.79M | $50.13M | $50.46M | $45.47M | $60.72M | $47.51M | $48.46M | $41.68M | $66.92M | $41.65M | $38.87M | $74.30M |
| High Forecast | $73.41M | $69.19M | $60.24M | $66.44M | $60.04M | $60.46M | $54.00M | $88.16M | $61.01M | $56.73M | $46.79M | $80.15M | $60.16M | $50.46M | $45.47M | $72.86M | $47.51M | $48.46M | $41.68M | $80.31M | $41.65M | $38.87M | $89.16M |
| Low Forecast | $73.41M | $69.19M | $60.24M | $66.44M | $60.04M | $59.49M | $54.00M | $58.78M | $56.99M | $53.00M | $46.79M | $53.43M | $40.11M | $50.46M | $45.47M | $48.57M | $47.51M | $48.46M | $41.68M | $53.54M | $41.65M | $38.87M | $59.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.05% | 1.02% | 1.28% | 1.46% | 1.00% | 1.14% | 0.85% | 0.97% | 1.00% | 1.08% | 0.64% | 6.01% | 0.58% | 1.24% |
Royalty Pharma's average Quarter SG&A projection for Dec 23 is $59.00M, based on 2 Wall Street analysts, with a range of $56.99M to $61.01M. The forecast indicates a 3.08% rise compared to RPRX last annual SG&A of $57.23M (Sep 23).
Royalty Pharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $0.16 | $0.51 | $0.76 | $-1.39 | $0.50 | $0.70 | $-0.09 | $0.02 | $0.24 | $1.08 | $0.18 | $0.44 | $0.79 | $0.09 |
| Avg Forecast | $1.36 | $1.10 | $1.11 | $1.01 | $1.07 | $0.93 | $0.97 | $0.99 | $1.01 | $0.77 | $0.83 | $1.27 | $1.47 | $0.71 | $0.78 | $0.73 | $0.78 | $0.70 | $0.70 | $0.66 | $0.70 | $0.59 | $0.61 |
| High Forecast | $1.36 | $1.10 | $1.11 | $1.01 | $1.07 | $0.95 | $0.97 | $0.99 | $1.02 | $0.86 | $0.83 | $1.27 | $1.47 | $0.71 | $0.78 | $0.73 | $0.78 | $0.70 | $0.70 | $0.66 | $0.70 | $0.59 | $0.61 |
| Low Forecast | $1.36 | $1.10 | $1.11 | $1.01 | $1.07 | $0.89 | $0.97 | $0.99 | $1.00 | $0.68 | $0.83 | $1.27 | $1.47 | $0.71 | $0.78 | $0.73 | $0.78 | $0.70 | $0.70 | $0.66 | $0.70 | $0.59 | $0.61 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.21% | 0.61% | 0.60% | -0.94% | 0.71% | 0.90% | -0.13% | 0.02% | 0.34% | 1.54% | 0.27% | 0.62% | 1.33% | 0.15% |
According to 2 Wall Street analysts, Royalty Pharma's projected average Quarter EPS for Dec 23 is $1.01, with a low estimate of $1.00 and a high estimate of $1.02. This represents a 531.27% increase compared to RPRX previous annual EPS of $0.16 (Sep 23).
Royalty Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KNTE | Kinnate Biopharma | $2.65 | $30.00 | 1032.08% | Hold |
| CVAC | CureVac | $2.71 | $29.00 | 970.11% | Buy |
| PRME | Prime Medicine | $3.96 | $17.25 | 335.61% | Buy |
| APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| ADPT | Adaptive Bio | $5.26 | $12.33 | 134.41% | Hold |
| IOVA | Iovance Biotherapeutics | $11.44 | $21.00 | 83.57% | Buy |
| RPRX | Royalty Pharma | $27.20 | $43.33 | 59.30% | Buy |
| ASND | Ascendis Pharma | $125.77 | $190.21 | 51.24% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| BGNE | BeiGene | $207.25 | $255.80 | 23.43% | Buy |
| BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| RPHM | Reneo Pharmaceuticals | $18.20 | $18.00 | -1.10% | Buy |
| DNA | Ginkgo Bioworks | $7.63 | $7.34 | -3.80% | Buy |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.70 | $5.33 | -6.49% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| IKNA | Ikena Oncology | $1.72 | $1.33 | -22.67% | Buy |
RPRX Forecast FAQ
Is Royalty Pharma a good buy?
Yes, according to 6 Wall Street analysts, Royalty Pharma (RPRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of RPRX's total ratings.
What is RPRX's price target?
Royalty Pharma (RPRX) average price target is $43.33 with a range of $28 to $51, implying a 59.30% from its last price of $27.2. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Royalty Pharma stock go up soon?
According to Wall Street analysts' prediction for RPRX stock, the company can go up by 59.30% (from the last price of $27.2 to the average price target of $43.33), up by 87.50% based on the highest stock price target, and up by 2.94% based on the lowest stock price target.
Can Royalty Pharma stock reach $40?
RPRX's average twelve months analyst stock price target of $43.33 supports the claim that Royalty Pharma can reach $40 in the near future.
What are Royalty Pharma's analysts' financial forecasts?
Royalty Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.69B (high $2.69B, low $2.68B), average EBITDA is $1.61B (high $1.64B, low $1.57B), average net income is $1.84B (high $1.87B, low $1.8B), average SG&A $247.49M (high $262.67M, low $232.31M), and average EPS is $3.95 (high $3.97, low $3.91). RPRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.13B (high $3.13B, low $3.13B), average EBITDA is $2.26B (high $2.26B, low $2.26B), average net income is $2.73B (high $2.73B, low $2.73B), average SG&A $269.29M (high $269.29M, low $269.29M), and average EPS is $4.58 (high $4.58, low $4.58).
Did the RPRX's actual financial results beat the analysts' financial forecasts?
Based on Royalty Pharma's last annual report (Dec 2022), the company's revenue was $2.24B, which missed the average analysts forecast of $2.78B by -19.40%. Apple's EBITDA was $983.17M, missing the average prediction of $993.23M by -1.01%. The company's net income was $42.83M, missing the average estimation of $959.09M by -95.53%. Apple's SG&A was $227.3M, beating the average forecast of $206.78M by 9.92%. Lastly, the company's EPS was $0.098, missing the average prediction of $3.69 by -97.35%. In terms of the last quarterly report (Sep 2023), Royalty Pharma's revenue was $536.31M, missing the average analysts' forecast of $631.74M by -15.11%. The company's EBITDA was $167.95M, missing the average prediction of $455.79M by -63.15%. Royalty Pharma's net income was $72.11M, missing the average estimation of $459.35M by -84.30%. The company's SG&A was $57.23M, beating the average forecast of $54.37M by 5.27%. Lastly, the company's EPS was $0.16, missing the average prediction of $0.77 by -79.21%